Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary BioWorld Today: Acceleron Secures $30M in Series B
BioWorld Today: Acceleron Secures $30M in Series B BioWorld Today, August 3, 2006
View HTML
Toggle Summary Acceleron Pharma Closes $30M Series B Financing
Acceleron Pharma Closes $30M Series B Financing CAMBRIDGE, MA – August 2, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, today announced that it secured a $30 million Series B financing.
View HTML
Toggle Summary BioCentury: Acceleron: Value in the Wallflower
BioCentury: Acceleron: Value in the Wallflower BioCentury, July 17, 2006
View HTML
Toggle Summary Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss
Acceleron Becomes a Clinical-Stage Company
View HTML
Toggle Summary Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer
Dr. Sherman’s Expertise in Building a Clinical Development Organization and Advancing Programs Through Regulatory Approval a Key Addition to the Management Team
View HTML
Toggle Summary Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors
Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors CAMBRIDGE, MA – June 14, 2004 – Acceleron Pharma announced today the appointment of Glenn Batchelder as president and CEO and a member of the board of directors.
View HTML
Toggle Summary Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding
Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding BOSTON, MA – February 13, 2004 – Acceleron Pharma, a biopharmaceutical company developing drugs to treat musculoskeletal and metabolic disorders, announced today that it has
View HTML